A

Soojin Jeon, Jihye Maeng, Jiwon Lee, Young-Min Kim, Gaewon Nam

Abstract read

In one paragraph

Article in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Soojin JeonDepartment of Integrative Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.ORCID 0009-0006-2045-9793

Jihye MaengDepartment of Integrative Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.ORCID 0009-0002-4333-9023

Jiwon LeeDepartment of Integrative Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.ORCID 0009-0009-7862-5143

Young-Min KimDepartment of Biological Science and Biotechnology, College of Life Science and Nano Technology, Hannam University, Daejeon 34054, Republic of Korea.

Gaewon NamDepartment of Integrative Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.ORCID 0000-0002-4623-588X

Funding

Ministry of SMEs and Startups S3460045Ministry of Trade, Industry and Energy RS-2024-00418203

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic skin disorder driven by Th2 immune dysregulation, persistent inflammation, and epidermal barrier defects. Oxidative stress acts as a major upstream factor in this process, amplifying inflammatory signals and worsening disease severity. While current treatments relieve acute symptoms, long-term application is often constrained by side effects and poor barrier restoration, pointing to a need for safer, multifaceted alternatives. Here, we formulated a complex of

Indexed as

antioxidant activityatopic dermatitiscopper-tripeptide-1GHK-Cukeratinocyte regenerationskin inflammationTh2 cytokinesTorilis japonica extract

Identifiers

PMID42510549

DOI10.3390/antiox15070818

PMCPMC13405852

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.